According to CoinMeta, the stock price of Moderna soared by 177% on Wednesday, closing at $174.38. This increase was due to Moderna and Merck announcing that their personalized melanoma vaccine had achieved its main objectives in phase three clinical trials. However, there is still disagreement on Wall Street regarding the true significance of this sharp rise in stock prices. Analysts have varying opinions on the prospects of Moderna's cancer vaccine; some see it as an important beginning, while others believe that the stock price has risen too quickly. According to Barclays's predictions, the vaccine could generate approximately $3 billion in revenue annually by 2035. Nevertheless, the stock price increase on Wednesday caused Moderna's market value to rise by about $44 billion in a single day, exceeding the reasonable range of potential vaccine revenue.